Receipt date: 06/19/2008 Doc code:IDS

Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (03-08)
Approved for use through 05/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number		10581000
INFORMATION BIGGLOOUSE	Filing Date		2007-05-10
INFORMATION DISCLOSURE	First Named Inventor	ı -	er Woscholski
(Not for submission under 37 CFR 1.99)	Art Unit		4044 1621
(Not for Submission under 57 STR 1.55)	Examiner Name	Por	fírio Nazario-Gonzalez
	Attorney Docket Numb	er	4033.3003 US

U.S.PATENTS										
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D)ate	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Releva Figures Appear		
	1									
If you wis	h to ac	ı dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.			
			U.S.P	ATENT	APPLI	CATION PUBI	LICATIONS			
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ition			Relev	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
/P.N./	1	20030055106	A1	2003-03	3-20	Faure, Robert et al.				
If you wis	h to ac	dd additional U.S. Publi	shed Ap	plication	citation	n information p	olease click the Add	d butto	on.	
				FOREIG	SN PAT	ENT DOCUM	ENTS			
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i		Kind Code ⁴	Publication Date	Name of Patented Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
/P.N./	1	00/57860	WO		A2	2000-10-05	Centre for Translati Research in Cance			
/P.N./	2	2004/018655	WO		A2	2004-03-04	Neuronova AB, Sw	ed.		
/P.N./	3	2 396 106	GB		А	2004-06-16	Johnson & Johnson Medical Limited, Uh			

Receipt date: 06/19/2008 Application Number 10581000 Filing Date 2007-05-10 **INFORMATION DISCLOSURE** First Named Inventor Rudiger Woscholski STATEMENT BY APPLICANT **4644** 1621 Art Unit (Not for submission under 37 CFR 1.99) **Examiner Name** Porfirio Nazario-Gonzalez 4033.3003 US Attorney Docket Number

		NON-PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T 5
/P.N./	1	SCHMID, Annette C., et al., "Bisperoxovanadium compounds are potent PTEN inhibitors," FEBS Letters, 566: 35-38 (2004).	
/P.N./	2	NOLTE, Lorraine A., et al., "A peroxovanadium compound stimulates muscle glucose transport as powerfully as insulin and contractions combined," Diabetes, 52(8): 1918-1925 (2003).	
/P.N./	3	BAND, Christian J., et al., "Early signaling events triggered by peroxovanadium [bpV(phen)] are insulin receptor kinase (IRK)-dependent: specificity of inhibition of IRK-associated protein tyrosine phosphatase(s) by bpV(phen)," Molecular Endocrinology, 11(13): 1889-1910 (1997).	
/P.N./	4	BAND, Christian J. and POSNER, Barry I., "Phosphatidylinositol 3'-Kinase and p70s6k are Required for Insulin but not Bisperoxovanadium 1, 10-phenanthroline (bpv(phen)) Inhibition of Insulin-like Growth Factor Binding Protein Gene Expression," J. Biological Chemistry, 272(1): 138-145 (1997).	
/P.N./	5	BARAT, Corrine and TREMBLAY, Michael J., "Treatment of Human T Cells with Bisperoxovanadium Phosphotyrosyl Phosphatase Inhibitors Leads to Activation of Cyclooxygenase-2 Gene," J. Biological Chemistry, 278(9): 6992-7000 (2002).	
/P.N./	6	SASAGAWA, Takahiro, et al., "Bis(6-ethylpicolinato)oxovanadium(IV) Complex with Normoglycemic Activity in KK-Ay Mice," J. Inorganic Biochemistry, 88(1): 108-112 (2002).	
/P.N./	7	KOZLOV, Alexander, et al., "Zeolite-encapsulated vanadium picolinate peroxo complexes active for catalytic hydrocarbon oxidations," J. Molecular Catalysis A: Chemical, 137: 223-237 (1999).	
/P.N./	8	POSNER, B.I., et al., "Peroxovanadium Compounds. A New Class of Potent Phosphotyrosine Phosphatase Inhibitors Which are Insulin Mimetics, J. Biol. Chem., 269 (6): 4596-4604 (1994).	
/P.N./	9	CUNCIC, C., et al., "Vanadate Inhibition of Protein Tyrosine Phosphatases in Jurkat Cells: Modulation by Redox State," J. Biol. Inorg. Chem., 4: 354-359 (1999).	

Receipt	date	e: 06/19/2008	Application Number		10581000	
INFORMATION BIOOLOGUES		Filing Date 2007-05-10				
			First Named Inventor	Rudig	ger Woscholski	
⁻	Chem., 272(2): 843-851 (1997). RUMORA, L., et al., "Differentia	Art Unit	-4644 1621			
(NOT IOF	Subin	ission under 37 CFK 1.99)	Examiner Name	Por	firio Nazario-Gonzalez	
		Attorney Docket Numb	per	4033.3003 US		
/P.N./	10	HUYER, G., et al., "Mechanism of Chem., 272(2): 843-851 (1997).	Inhibition of Protein-Tyrosi	ne Pho:	sphatases by Vanadate and Pervanadate," J. Biol.	
/P.N./	/P.N./ 11 RUMORA, L., et al., "Differential Regulation of JNK Activation and MKP-1 Expression by Peroxovanadium Complexes," Neurochem. Int., 38: 341-347 (2001).					
I	I					I

/P.N./	10	HUYER, G., et al., "Mechanism of Inhibition of Protein-Tyrosine Phosphatases by Vanadate and Pervanadate," J. Biol. Chem., 272(2): 843-851 (1997).						
/P.N./	11	RUMORA, L., et al., "Differential Regulation of JNK Activation and MKP-1 Expression by Peroxovanadium Complexes," Neurochem. Int., 38: 341-347 (2001).						
/P.N./	12	SHISHEVA, A. and SHECHTER, Y., et al., "Mechanism of Pervanadate Stimulation and Potentiation of Insulin-Activated Glucose Transport in Rat Adipocytes: Dissociation from Vanadate Effect," Endocrinology, 133(4): 1562-1568 (1993).						
/P.N./	13	WILDEN, P.A and BROADWAY, D., "Combination of Insulinomimetic Agents H2O2 and Vanadate Enhances Insulin Receptor Mediated Tyrosine Phosphorylation of IRS-1 Leading to IRS-1 Association with the Phosphatidylinositol 3-kinase," J. Cell Biochem., 58: 279-291 (1995).						
/P.N./	14	SHECHTER, Y., "Insulin-Mimetic Effects of Vanadate. Possible Implications for Future Treatment of Diabetes," Diabetes, 39: 1-5 (1990).						
/P.N./	STEPHENS, L.R., et al., "Agonist-Stimulated Synthesis of Phosphatidylinositol(3,4,5)-Trisphosphate: A New Intracellular Signalling System?" Biochim. et Biophys. Acta, 1179: 27-75 (1993).							
If you wis	h to a	dd additional non-patent literature document citation	information please click the Add bu	tton				
		EXAMINER SIG						
Examiner Signature Porfirio Nazario Gonzalez/ Date Considered 11/20/2009			11/20/2009					
		nitial if reference considered, whether or not citation i conformance and not considered. Include copy of the		•				
Standard ST 4 Kind of doo	F.3). ³ F cument	of USPTO Patent Documents at www.USPTO.GOV or MPEP 901 For Japanese patent documents, the indication of the year of the by the appropriate symbols as indicated on the document under anslation is attached.	reign of the Emperor must precede the serial	number of the patent doc	ument.			